Screener
McKesson MCK North American Pharmaceutical — Asset impairments and accelerated depreciation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept mck:AssetImpairmentChargesIncludingAcceleratedDepreciation.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | Three Months Ended June 30, 2026 / North American Pharmaceutical (1) | Three Months Ended June 30, 2026 / Prescription Technology Solutions (1) | Three Months Ended June 30, 2026 / Medical-Surgical Solutions (1) | Three Months Ended June 30, 2026 / Corporate (1) | Total |
|---|---|---|---|---|---|
| Severance and employee-related costs, net | — | $11 | $14 | $7 | $32 |
| Exit and other-related costs (2) | 1 | 10 | 9 | 37 | 57 |
| Asset impairments and accelerated depreciation | 1 | 40 | — | 6 | 47 |
| Total | $2 | $61 | $23 | $50 | $136 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's north american pharmaceutical — asset impairments and accelerated depreciation?
- McKesson (MCK) reported north american pharmaceutical — asset impairments and accelerated depreciation of $1M in Q2 2026.
- What does north american pharmaceutical — asset impairments and accelerated depreciation mean?
- This metric represents non-cash charges taken when the carrying value of assets in the North American Pharmaceutical segment exceeds their fair value, or when the useful life of assets is shortened due to restructuring. It reflects the write-down of tangible or intangible assets that are no longer expected to provide future economic benefit.
Ask your AI about McKesson's north american pharmaceutical — asset impairments and accelerated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude